Literature DB >> 16126333

Guidelines on testicular cancer.

Peter Albers1, Walter Albrecht, Ferran Algaba, Carsten Bokemeyer, Gabriella Cohn-Cedermark, Alan Horwich, Olbjoern Klepp, M Pilar Laguna, Giorgio Pizzocaro.   

Abstract

OBJECTIVE: To up-date the 2001 version of the EAU testicular cancer guidelines.
METHODS: A non-structured literature review until January 2005 using the MEDLINE database has been performed. Literature has been classified according to evidence-based medicine levels.
RESULTS: Testicular cancer is a highly curable disease. Excellent cure rates have been achieved by standardization of treatment, interdisciplinary management, and tremendous success in performing clinical trials. Currently, the aims of testicular cancer treatment are as follows: for patients with low-stage disease, a reduction in treatment is proposed to improve long-term toxicity in these patients with unaltered life expectancy; for about 10% of patients with advanced disease and poor prognosis, intensification of treatment (including high-dose chemotherapy and new drugs as well as aggressive surgical approaches) is being investigated to improve long-term cure rates.
CONCLUSION: Guidelines will improve clinical practice only if they are regularly updated. This update presents the state-of-the-art management of testicular cancer patients in 2005.

Entities:  

Mesh:

Year:  2005        PMID: 16126333     DOI: 10.1016/j.eururo.2005.06.019

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  31 in total

1.  Impact of the chemotherapy cocktail used to treat testicular cancer on the gene expression profile of germ cells from male Brown-Norway rats.

Authors:  Geraldine Delbès; Donovan Chan; Pirjo Pakarinen; Jacquetta M Trasler; Barbara F Hales; Bernard Robaire
Journal:  Biol Reprod       Date:  2008-11-05       Impact factor: 4.285

2.  Asymptomatic Sertoli cell tumour diagnosed during azoospermia work-up.

Authors:  Hakan Ozturk; Musa Saracoglu; Tarik Zengin; Oya Nermin Sivrikoz; Hüseyin Serhat Kerman; Saban Adakan
Journal:  Asian J Androl       Date:  2013-10-14       Impact factor: 3.285

Review 3.  Current Concepts in Management of Stage I NSGCT.

Authors:  Puneet Ahluwalia; Gagan Gautam
Journal:  Indian J Surg Oncol       Date:  2016-12-17

4.  High risk NSGCT: case for surveillance.

Authors:  David Michael Kakiashvili; Alvaro Zuniga; Michael A S Jewett
Journal:  World J Urol       Date:  2009-07-16       Impact factor: 4.226

5.  Osteolytic bone destruction resulting from relapse of a testicular tumour 23 years after inguinal orchiectomy and adjuvant chemotherapy: a case report.

Authors:  Christos Kalaitzis; Athanasios Bantis; Georgios Tsakaldimis; Stylianos Giannakopoulos; Efthimios Sivridis; Stavros Touloupidis
Journal:  J Med Case Rep       Date:  2009-07-31

6.  Fertility preservation for cancer patients: a review.

Authors:  Tosin Ajala; Junaid Rafi; Peter Larsen-Disney; Richard Howell
Journal:  Obstet Gynecol Int       Date:  2010-03-31

7.  Management of poor-prognosis testicular germ cell tumors.

Authors:  Kiranpreet Khurana; Timothy D Gilligan; Andrew J Stephenson
Journal:  Indian J Urol       Date:  2010 Jan-Mar

Review 8.  Case report: soft tissue metastasis from immature teratoma of the testis: second case report and review of the literature.

Authors:  Ahmet Bilici; Bala Basak Oven Ustaalioglu; Mesut Seker; Sibel Kayahan
Journal:  Clin Orthop Relat Res       Date:  2009-11-25       Impact factor: 4.176

9.  Clinical and genetic aspects of testicular germ cell tumours.

Authors:  Martijn F Lutke Holzik; Rolf H Sijmons; Josette Ehm Hoekstra-Weebers; Dirk T Sleijfer; Harald J Hoekstra
Journal:  Hered Cancer Clin Pract       Date:  2008-02-15       Impact factor: 2.857

10.  Late recurrence and second primary malignancy among 139 patients with germ cell tumors: long-term outcome of the disease in a single-center experience.

Authors:  Shunsuke Sato; Toshiaki Tanaka; Atsushi Takahashi; Masamichi Sasai; Hiroshi Kitamura; Naoya Masumori; Taiji Tsukamoto
Journal:  Jpn J Clin Oncol       Date:  2009-11-10       Impact factor: 3.019

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.